CXCL13 Neutralization Attenuates Neuropsychiatric Manifestations in Lupus-Prone Mice

Neuropsychiatric lupus (NPSLE), the nervous system presentation of systemic lupus erythematosus (SLE), remains challenging to treat due to its unclear pathogenesis and lack of available targeted therapies. A potential contributor to disease progression is brain tertiary lymphoid structures (TLS); th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Michelle W. Huang, Ariel D. Stock, Chaim Putterman
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	CXCL13 SLE neuropsychiatric lupus (NPSLE) MRL/lpr tertiary lymphoid structures Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/6a888c1eec9e4fc79ea2a60fb9c1c1c5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6a888c1eec9e4fc79ea2a60fb9c1c1c5
record_format	dspace
spelling	oai:doaj.org-article:6a888c1eec9e4fc79ea2a60fb9c1c1c52021-11-12T06:17:48ZCXCL13 Neutralization Attenuates Neuropsychiatric Manifestations in Lupus-Prone Mice1664-322410.3389/fimmu.2021.763065https://doaj.org/article/6a888c1eec9e4fc79ea2a60fb9c1c1c52021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.763065/fullhttps://doaj.org/toc/1664-3224Neuropsychiatric lupus (NPSLE), the nervous system presentation of systemic lupus erythematosus (SLE), remains challenging to treat due to its unclear pathogenesis and lack of available targeted therapies. A potential contributor to disease progression is brain tertiary lymphoid structures (TLS); these ectopic lymphoid follicles that can develop tissue-targeted antibodies have recently been described in the MRL/lpr lupus mouse strain, a classic model for studying NPSLE. The brains of MRL/lpr mice show a significant increase of CXCL13, an important chemokine in lymphoid follicle formation and retention that may also play a role in the disease progression of NPSLE. The aim of the present study was to inhibit CXCL13 and examine the effect of this intervention on lymphoid formation and the development of neurobehavioral manifestations in lupus mice. Female MRL/lpr mice were injected with an anti-CXCL13 antibody, an IgG1 isotype-matched antibody, or PBS either three times a week for 12 weeks intraperitoneally (IP) starting at 6-8 weeks of age, or continuously intracerebroventricularly (ICV) with an osmotic pump over a two-week period starting at 15 weeks of age. Cognitive dysfunction and depression-like behavior were assessed at the end of treatment. When treatment was delivered IP, anti-CXCL13 treated mice showed significant improvement in cognitive function when compared to control treated mice. Depression-like behavior was attenuated as well. Furthermore, mice that received anti-CXCL13 by the ICV route showed similar beneficial effects. However, the extent of lymphocyte infiltration into the brain and the general composition of the aggregates were not substantively changed by anti-CXCL13 irrespective of the mode of administration. Nevertheless, analysis of brain gene expression in anti-CXCL13 treated mice showed significant differences in key immunological and neuro-inflammatory pathways that most likely explained the improvement in the behavioral phenotype. Our results indicate that CXCL13 affects the behavioral manifestations in the MRL/lpr strain and is important to the pathogenesis of murine NPSLE, suggesting it as a potential therapeutic target.Michelle W. HuangAriel D. StockChaim PuttermanChaim PuttermanChaim PuttermanChaim PuttermanFrontiers Media S.A.articleCXCL13SLEneuropsychiatric lupus (NPSLE)MRL/lprtertiary lymphoid structuresImmunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	CXCL13 SLE neuropsychiatric lupus (NPSLE) MRL/lpr tertiary lymphoid structures Immunologic diseases. Allergy RC581-607
spellingShingle	CXCL13 SLE neuropsychiatric lupus (NPSLE) MRL/lpr tertiary lymphoid structures Immunologic diseases. Allergy RC581-607 Michelle W. Huang Ariel D. Stock Chaim Putterman Chaim Putterman Chaim Putterman Chaim Putterman CXCL13 Neutralization Attenuates Neuropsychiatric Manifestations in Lupus-Prone Mice
description	Neuropsychiatric lupus (NPSLE), the nervous system presentation of systemic lupus erythematosus (SLE), remains challenging to treat due to its unclear pathogenesis and lack of available targeted therapies. A potential contributor to disease progression is brain tertiary lymphoid structures (TLS); these ectopic lymphoid follicles that can develop tissue-targeted antibodies have recently been described in the MRL/lpr lupus mouse strain, a classic model for studying NPSLE. The brains of MRL/lpr mice show a significant increase of CXCL13, an important chemokine in lymphoid follicle formation and retention that may also play a role in the disease progression of NPSLE. The aim of the present study was to inhibit CXCL13 and examine the effect of this intervention on lymphoid formation and the development of neurobehavioral manifestations in lupus mice. Female MRL/lpr mice were injected with an anti-CXCL13 antibody, an IgG1 isotype-matched antibody, or PBS either three times a week for 12 weeks intraperitoneally (IP) starting at 6-8 weeks of age, or continuously intracerebroventricularly (ICV) with an osmotic pump over a two-week period starting at 15 weeks of age. Cognitive dysfunction and depression-like behavior were assessed at the end of treatment. When treatment was delivered IP, anti-CXCL13 treated mice showed significant improvement in cognitive function when compared to control treated mice. Depression-like behavior was attenuated as well. Furthermore, mice that received anti-CXCL13 by the ICV route showed similar beneficial effects. However, the extent of lymphocyte infiltration into the brain and the general composition of the aggregates were not substantively changed by anti-CXCL13 irrespective of the mode of administration. Nevertheless, analysis of brain gene expression in anti-CXCL13 treated mice showed significant differences in key immunological and neuro-inflammatory pathways that most likely explained the improvement in the behavioral phenotype. Our results indicate that CXCL13 affects the behavioral manifestations in the MRL/lpr strain and is important to the pathogenesis of murine NPSLE, suggesting it as a potential therapeutic target.
format	article
author	Michelle W. Huang Ariel D. Stock Chaim Putterman Chaim Putterman Chaim Putterman Chaim Putterman
author_facet	Michelle W. Huang Ariel D. Stock Chaim Putterman Chaim Putterman Chaim Putterman Chaim Putterman
author_sort	Michelle W. Huang
title	CXCL13 Neutralization Attenuates Neuropsychiatric Manifestations in Lupus-Prone Mice
title_short	CXCL13 Neutralization Attenuates Neuropsychiatric Manifestations in Lupus-Prone Mice
title_full	CXCL13 Neutralization Attenuates Neuropsychiatric Manifestations in Lupus-Prone Mice
title_fullStr	CXCL13 Neutralization Attenuates Neuropsychiatric Manifestations in Lupus-Prone Mice
title_full_unstemmed	CXCL13 Neutralization Attenuates Neuropsychiatric Manifestations in Lupus-Prone Mice
title_sort	cxcl13 neutralization attenuates neuropsychiatric manifestations in lupus-prone mice
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/6a888c1eec9e4fc79ea2a60fb9c1c1c5
work_keys_str_mv	AT michellewhuang cxcl13neutralizationattenuatesneuropsychiatricmanifestationsinlupuspronemice AT arieldstock cxcl13neutralizationattenuatesneuropsychiatricmanifestationsinlupuspronemice AT chaimputterman cxcl13neutralizationattenuatesneuropsychiatricmanifestationsinlupuspronemice AT chaimputterman cxcl13neutralizationattenuatesneuropsychiatricmanifestationsinlupuspronemice AT chaimputterman cxcl13neutralizationattenuatesneuropsychiatricmanifestationsinlupuspronemice AT chaimputterman cxcl13neutralizationattenuatesneuropsychiatricmanifestationsinlupuspronemice
_version_	1718431175148568576

CXCL13 Neutralization Attenuates Neuropsychiatric Manifestations in Lupus-Prone Mice

Ejemplares similares